Alphatec Holdings (ATEC) is back in focus after missing Q1 2026 revenue estimates, cutting its full year outlook on softer deliveries, and facing fresh securities law investigations that have sharpened investor attention.

Despite the legal overhang and guidance cut, the recent 7 day share price return of 10.43% and 30 day share price return of 9.84% sit against a much weaker 90 day share price return, which is down 34.76%, and a year to date share price return that is down 60.21%. Over longer horizons, the 1 year total shareholder return is down 32.35% and the 3 year total shareholder return is down 47.36%, suggesting recent strength is more a short term rebound than a shift in the longer trend.

If this kind of volatility has you looking beyond a single spine surgery stock, it could be a good moment to scan the wider healthcare technology space using the 39 healthcare AI stocks

With Alphatec trading at $8.26, a market cap of about $1.2b and an intrinsic value estimate implying a sizeable discount, yet facing Q1 weakness and legal scrutiny, is this a genuine opportunity or is the market already pricing in future growth?

Most Popular Narrative: 52.3% Undervalued

At a last close of $8.26 versus a narrative fair value of $17.33, Alphatec is framed as heavily discounted, with that gap built on detailed growth and margin assumptions.

Expanding surgeon adoption, strong same-store sales growth, and increasing procedural volume signal Alphatec's ability to leverage the aging population and rising prevalence of spinal conditions, driving substantial and durable revenue growth.

Want to see what is baked into that $17.33 figure? The narrative leans on brisk top line expansion, a swing to profitability, and a richer earnings multiple. The exact mix of growth, margins, and valuation is where the story gets interesting.

Result: Fair Value of $17.33 (UNDERVALUED)

However, this hinges on spine procedure volumes holding up and Alphatec keeping its operating losses and heavy R&D spend from putting fresh pressure on cash flow.

Next Steps

Seen enough to form an early view on Alphatec, or still on the fence with both risks and rewards in play? If you want to move quickly and weigh the legal, financial, and growth angles side by side, start by reviewing the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Alphatec has sharpened your thinking, do not stop there. Broaden your watchlist with focused stock ideas that match how you like to invest.

• Hunt for quality at a discount by scanning 46 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect them.
• Prioritise resilience by checking 63 resilient stocks with low risk scores where companies score well on financial strength and business stability.
• Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.